226-240 of 379

Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies

The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease

Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions

Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients

DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target

Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
On the Frontlines of CIDPIdentifying CIDP: A Guide to Risk Profiles and Clinical Presentation
- advertisement

Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease

Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease

Identifying C3G: Key Diagnostic Considerations and Challenges
On the Frontlines of C3GIdentifying C3G: Key Diagnostic Considerations and Challenges

Transforming C3G Care: New Advances in Targeted Treatment
On the Frontlines of C3GTransforming C3G Care: New Advances in Targeted Treatment

Gene Therapy Safety in DMD: How to Identify Common Immune Reactions
NeuroFrontiersGene Therapy Safety in DMD: How to Identify Common Immune Reactions

Optimizing DMD Care Through Multidisciplinary Collaboration
NeuroFrontiersOptimizing DMD Care Through Multidisciplinary Collaboration
- advertisement

Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod

Empowering Patients with CIDP: Education, Support, and Personalized Care Strategies
On the Frontlines of CIDPEmpowering Patients with CIDP: Education, Support, and Personalized Care Strategies

New Frontiers in CIDP Care: Exploring Approved and Emerging Therapies
On the Frontlines of CIDPNew Frontiers in CIDP Care: Exploring Approved and Emerging Therapies


































